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Abstract  
Objectives: The Cystic Fibrosis (CF) International Mental Health Guidelines Committee 
published consensus statements for screening and treating depression and anxiety in 
individuals with CF and their caregivers. This work aimed to evaluate the dissemination and 
implementation of the guidelines in Europe two years following their publication.                                                                                                           
Methods: A 28-item survey was developed by the multidisciplinary ECFS Mental Health 
Working Group and emailed to approximately 300 CF centres across Europe. The survey 
evaluated (a) who should be responsible for mental health (MH) care, (b) the current 
awareness and agreement of the guidelines, (c) the provision of recommended MH screening 
and follow-up care, and (d) successes, barriers and required resources/training needs.                                                    
Results: Responses were received from 187 centres (28 countries represented). There was 
consensus that a psychologist should be responsible for MH care, although members of the 
multidisciplinary team (MDT) believed they should also share this responsibility. Sixty-two 
percent of respondents were aware of the guidelines; 82% percent fully, and 12% partially, 
agreed with them. Fifty percent (94 centres) had implemented screening. In the past year 
approximately 6000 patients and 2000 caregivers had been screened, with 80% of 
respondents using the recommended screening tools. Respondents reported 551 referrals for 
moderate/severe psychopathology and 84 urgent suicide ideation referrals.                                                                                                                    
Conclusions: The challenges of different healthcare systems and language barriers are being 
overcome with a greater awareness of the importance of mental health among the MDT. MH 
screening is feasible and gaining momentum in both Western and Eastern Europe. 
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1. Introduction  
 Elevated symptoms of depression or anxiety in people with cystic fibrosis have been 
associated with poor health outcomes1,2, poor adherence3-4, poor quality of life5, more 
frequent hospitalizations and increased health care costs2. The recent TIDES study (The 
International Depression and anxiety Epidemiological Study) screened 6,088 patients (age 
12+) and 4,102 parents across nine countries6. Elevated symptoms of depression were found 
in 10% of adolescents, 19% of adults, 37% of mothers and 31% of fathers; elevated symptoms 
of anxiety were reported by 22% of adolescents, 32% of adults, 48% of mothers and 36% of 
fathers. Of 1,122 parent-teen dyads, if either parent screened positive, the adolescent was 
twice as likely to report elevated symptoms of depression or anxiety.  
    
The International Mental Health Guidelines Committee (IMHGC) in Cystic Fibrosis (established 
and supported by the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society) set 
up consensus statements for screening and treating depression and anxiety in individuals with 
CF and their caregivers. These statements are advocated in the published guidelines7. The 
guidelines were informed by feedback from the CF clinical, parent and patient communities 
in Europe and the US. They recommend annual anxiety and depression screening for adults 
and adolescents (12+ years), and at least one primary caregiver of children under 18 years. 
Those with elevated symptoms are recommended to receive a formal psychological 
assessment prior to receiving evidence-based psychological and/or psychopharmacological 
intervention.  A survey of 1454 international CF health professionals (Europe 48.9%; US 
44.8%), undertaken during the development of the guidelines, highlighted that Mental Health 
(MH) care delivery in CF was inadequate and highly variable across care centres and 
countries8. Seventy-two percent of respondents had no experience of MH screening and the 
majority did not have a colleague trained to manage mental health issues. Forty-eight 
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depression and anxiety screening measures were in use and 30% of respondents were 
unable/unsure if they could refer to MH clinicians in their hospital. Perceived barriers to MH 
screening included (a) lack of trained personnel to administer and score the measures, (b) 
time required and clinic flow disruption, and (c) problems with referrals and in-house capacity 
for interventions.    
 
The ECFS Mental Health Working Group (MHWG) is working with the European CF community 
to disseminate the guidelines across Europe. To facilitate implementation of annual MH 
screening, the MHWG has provided resources on the ECFS website 
(https://www.ecfs.eu/mental-health-working-group), recruited ‘country captains’ to assist 
with dissemination via national networks and provided opportunities for training. The 
dissemination and implementation of these guidelines across Europe, their effectiveness as 
determined by clinical outcome and as perceived by patients and caregivers has yet to be 
evaluated. The first step in this evaluation process is a survey to CF Centres which aimed to 
evaluate the dissemination and implementation of the MH guidelines in Europe two years 
following their publication.  
 
2. Methods  
2.1 Survey development and distribution 
A short, 28-item, survey (Online supplement 1) was developed by the multidisciplinary 
Research and Evaluation Sub-group of the ECFS Mental Health Working Group. The 
questionnaire evaluated (a) who should be responsible for MH care, (b) the current 
awareness and agreement of the guidelines, (c) the provision of the recommended MH 
screening and follow-up care, and (d) the successes of, and barriers to screening, and further 
resource/training needs. To aid completion and analyses of the questionnaire, forced choice 
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or free responses and the input of numerical/text data only fields were developed. The survey 
was piloted, via email link, to members of the MHWG not involved in its development. This 
led to improvements in the survey design prior to distribution to CF Centres. Amendments 
were made to the wording of items and response categories to enable their understanding 
by individuals whose first language was not English.  
 
Multiple ECFS (ECFS member database, ECFS conference attendees) and Psychosocial List-
serves were merged in an attempt to reach all CF Centres in Europe. To ensure the final list 
was concise, duplicated contact information was removed as well as identified contacts for 
whom the survey was not appropriate e.g. microbiologists and geneticists. The survey was 
administered using the web-based tool ‘SurveyMonkey’9 and distributed on 6th October 2017 
by email, via the ECFS portal, to 1,016 CF multidisciplinary team contacts across Europe, 
representing approximately 300 CF Centres (the accuracy of contact data in the List-serves is 
not guaranteed as many people use non-institutional email addresses). A single reminder was 
sent on the 25th October 2017. Additionally, the MHWG had established ‘country captains’ 
and they were asked to send the survey link to their specific national networks. The survey 
clearly requested only one response from a CF Centre.      
 
2.2 Data analyses                                                                                                                                                                                 
The data were downloaded from SurveyMonkey to SPSS version 24 and cleaned appropriately 
(finding and eliminating errors in the dataset e.g. duplicate cases, impossible values).  Multiple 
response frequencies and percentages of responses were determined. Comparisons of 
Eastern and Western European CF Centres were undertaken where sample numbers 
permitted10.  
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3. Results     
3.1 Respondents and location  
Responses were received from 187 CF Centres across 28 European countries, suggesting a 
response rate of approximately 62%. Two duplicates were detected (responses from the same 
centre). To standardise procedure and eliminate bias we accepted the first response to the 
survey in both instances. Table 1 provides the characteristics of CF Centres and the profession 
of those who completed the survey. The numbers of participants from each country are listed 
in online supplement 2.  
 
3.2 Responsibility for Mental Health 
Table 2 lists those with current responsibility for MH and provides the results to the question 
‘Who should be responsible for MH care?’ (multiple response options permitted). Seventy-
two percent of respondents reported that the psychologist was currently responsible for MH 
but when asked ‘who should be responsible’  this increased to 90%. However, it is clear that 
many members of the multidisciplinary team (MDT) believe that they too share some of the 
responsibility and it is noteworthy that whilst retaining overall responsibility, 86% of 
psychologists endorsed other team members too, suggesting that MH should be a ‘team 
approach’. 
 
3.3 Awareness/agreement of the guidelines  
Sixty-two percent of respondents were aware of the MH Guidelines. Of these, 82% fully and 
12% partially agreed with them. Reasons provided for partial agreement were (a) that the 
guidelines were felt to be too rigid when some teams have the ability to perform a more 
comprehensive assessment (7%), (b) some clinicians were uncomfortable screening parent 
caregivers (4%) and (c) the sensitivity of the screening tools were questioned (1%).  
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3.4 Current Mental health care and outcomes 
Fifty percent of centres (n=94, approximate total patients = 16,000) had implemented MH 
screening, with half of those able to integrate screening into their work schedule. Eighty 
percent of those screening were using the recommended instruments; the PHQ-8/9 and GAD-
7 (5% reported using additional measures to perform a more comprehensive assessment). 
Twenty percent were administering other anxiety and depression scales, with nine other 
validated scales reported by participants (listed in online supplement 3).  
 
The percentage of patients and caregivers screened in the past year varied across centres. Of 
those screening, forty-eight percent of paediatric centres and 43% of adult centres reported 
screening over 50% of patients in their clinic (with 32% of paediatric centres and 25% of adult 
centres screening more than 75%). Forty-six percent of paediatric centres had also screened 
more than 50% of caregivers. Some centres were just starting to screen with 22% of paediatric 
centres and 30% of adult centres screening <25% of their patients in the past year.  A total 
estimate of 6000 patients and 2000 caregivers were screened. The number of referred cases 
were obtained from 56% of centres who were screening, with 551 treatment referrals for 
moderate/severe psychopathology and 84 urgent suicide ideation referrals reported. The 
ability to provide follow-up referrals/treatment is highlighted in Figure 1. Of note, only 44% 
were always able to provide the recommended follow-up, and one-third of those screening 
reported that they did not have a plan developed for suicide risk. 
  
3.5 Benefits, barriers and further training needs  
Table 3 (values in parenthesis are from the pre-guidelines survey8) lists the benefits and 
barriers to MH screening and the further training needs. The main benefits of screening were 
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1) easier to initiate MH conversation, 2) greater awareness of MH among the MDT, patients 
and caregivers and 3) MH being destigmatised. The main barriers included 1) insufficient staff 
time and 2) lack of qualified MH personnel. Interestingly, the top training need was ‘Mental 
Health training for the CF team’. Other resources required included funds to support a MH 
professional, electronic tools for administration and scoring, access to a MH hotline for 
guidance (peer support / guidance from someone who has implemented the guidelines).   
 
3.6 Comparison of East and Western European Countries  
There were 14 Western and 14 Eastern European countries represented in the survey data 
with 150 and 35 CF Centres responding respectively. Nine Eastern European countries  (14 CF 
Centres) and 12 Western European countries (80 CF Centres) were screening. Comparisons of 
guidelines awareness, agreement and current MH care delivery are presented in Figure 2. 
There was no consistent pattern/difference observed between Eastern and Western 
European countries (overall, neither group fared better or worse than the other) concerning 
attitudes, screening implementation, suicide risk planning and follow-up referrals. Though, 
proportionally, respondents from Eastern Europe were more aware of the guidelines (Χ2 = 
14.51, p<0.01), whilst those from Western Europe were more able to screen (Χ2 = 15.72, 
p<0.01) and provide referral pathways within their team (Χ2 = 13.98, p<0.01).  
 
 
4. Discussion 
The benefits of MH screening are evident with greater awareness of the importance of MH 
among the CF team. Health professionals report being able to initiate MH conversations more 
easily with patients and caregivers. As expected, the current responsibility for MH rests 
mainly with the psychologist, but a notable finding was that members of the CF team believed 
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that they too share this responsibility. Indeed, the majority of psychologists were supportive 
of a ‘team approach’ to MH. This demands opportunities for MH training for the entire 
multidisciplinary team.  These data are specific to European countries where psychologists 
are employed to provide a range of psychological expertise in the management of chronic 
conditions. Over the last few years CF Centres in the US have expanded MH care. This has been 
sustained almost solely by social workers. More recently, the Cystic Fibrosis Foundation has funded 
Mental Health Coordinators to join the interdisciplinary CF team. Those appointed come from the 
disciplines of social work, psychology, counselling and psychiatry.  
 
The vast majority of those who were aware of the guidelines agreed with them. Of those who 
had reservations, the main reason for partial agreement was due to the uncertainty around 
screening caregivers. Some clinicians were uncomfortable screening parent caregivers when 
they are ‘not the patient’. There were difficulties concerning the ethics and logistics of 
caregiver depression and anxiety data storage; whether or not it should be enclosed within 
the child’s medical notes. Additionally, for some centres, suitable treatment referrals have 
proved problematic. These issues require consideration and may need to be addressed at 
country or centre level.   Over 90% of those aware of the guidelines fully agreed with (at least) 
screening people with CF for depression and anxiety annually using the PHQ-8/9 and GAD-7. 
Others were already implementing an annual comprehensive psychological screen, and this 
is the ideal where resources allow.  Only one respondent was not in favour of any type of MH 
screening.  
 
Thirty-eight percent of responding centres were not aware of the guidelines.  An aim of the 
ECFS MH Working Group is to disseminate the guidelines across Europe and this endeavour 
is ongoing.  This is being addressed by the active recruitment of ‘Country Captains’ to help 
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with language translations of resource materials. A positive, inadvertent consequence of the 
survey has been an introduction to the guidelines for those who were previously unaware of 
their existence.    
 
Eighty percent of those screening were using the recommended screening tools (of these, 5% 
were using the GAD-7 and PHQ-8/9 as part of a more wide-ranging assessment). However, 
20% were still using other screening tools. Nine other depression or anxiety validated 
measures were reported but this is a significant improvement from pre-guideline reports 
when 48 different screening tools were being used in clinical practice8.  The most employed 
non-recommended tool was the Hospital Anxiety and Depression Scale (HADS, n=9). This is 
not surprising as it was the main tool administered in the TIDES study, but was shown to 
underestimate depression and anxiety in CF6.  Indeed, recent work indicates that there is 
much more psychopathology in people with CF and their parent caregivers than was 
estimated by the TIDES study11. In comparison with formal face-to face psychological 
assessment, the GAD-7 and PHQ-8/9 were able to identify all those with the most severe 
psychopathology and all those who endorsed the suicide ideation screening item. For those 
reporting less severe difficulties on screening, agreement with formal assessment was less 
accurate. Typically, this was because people underestimated/underreported their symptoms 
at screening (with patients and caregivers requiring treatment referrals following 
psychological assessment)11.   
 
Screening cannot replace clinical judgement but is a first step in MH care.  The standardisation 
of screening tools is imperative and the PHQ-8/9 and GAD-7 are also the screening 
instruments of choice by national professional bodies12-18 as the items map onto current 
diagnostic criteria (DSM-519) and are available in many languages.  In Western European 
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countries where psychologists have been embedded in the CF team for many years it is typical 
for more comprehensive psychological assessments to occur. This is the ideal, but many 
countries and centres do not have this amenity. Following guideline recommendations, in 
particular, administering the standardised tools allows the data from those countries were 
resources are limited to contribute to larger research datasets (potentially including registry 
data).  
 
Respondents reported screening approximately 6000 patients and 2000 caregivers. Clearly, 
these are underestimates of MH guideline implementation as the data is only based on those 
responding to survey, but they highlight rapid commitment to the recommendations provided 
in the guidelines and demonstrate the feasibility of overcoming local barriers. The percentage 
of respondents able to provide preventative strategies was low (61%) in comparison with the 
ability to provide referrals within the team (78%). This may reflect a focus on ‘curative health 
care’ in most health care systems, hence the availability of referral pathways but less 
attention on prevention.   Even so, the ability to always provide follow-up referrals is currently 
less than optimal, with many centres unable to provide appropriate follow-up care or have a 
protocol for those presenting with suicide ideation. Prior to the commencement of screening, 
suitable resources need to be in place to ensure appropriate referrals.  Where there is no 
plan/follow-up protocol for suicide risk, this requires immediate attention. Indeed, regardless 
of whether these is a formal screening program in place or dedicated MH professions, CF 
centres may encounter an individual expressing hopelessness and suicidal ideation, and 
should be familiar with local pathways for further evaluation. 
 
Non-responder bias may have influenced the results of this survey. As a self-selecting group, 
it is possible that respondents were more interested and engaged in MH care. Additionally, 
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the questionnaire was distributed in English and this may have been a barrier to completion 
for non-native English speakers. To avoid the risk of being over-prescriptive (respondents 
were from 28 different countries/cultures with very different health systems), some 
questions were not operationally defined and this may have resulted in respondents 
interpreting questions in their own way.   However, the questionnaire was developed by, and 
piloted on, individuals from 13 different countries who have implemented screening and no 
operational issues were raised. Neither did respondents query the meaning of any questions 
in the comment boxes provided in the survey.    
 
The differential distribution of responses from across Europe is notable, with Eastern 
European participants in particular, underrepresented in the data. However, even though 
numbers for Eastern Europe are small for survey data, proportionally, there was no consistent 
pattern/difference observed between Eastern and Western European countries concerning 
attitudes and screening implementation. There does not appear to be the large chasm 
between East and West that might have been expected. This may be as a result of exposure 
to the guidelines given the MHWG’s efforts in engaging ‘Country captains’ to network in their 
country (24 have been recruited from Eastern Europe), translating the required resources into 
many languages and providing easy access, via the ECFS website, to the screening tools 
(translated into 30 languages). A continued focus on Eastern countries is essential, particularly 
as a recent Eastern European survey of 16 countries highlighted that CF Care is variable across 
Eastern Europe and only 8 countries reported that clinical psychologists were part of the CF 
team. A complete multidisciplinary team was only reported in only 2 countries20.  
 
Compared with the pre-guidelines survey8, barriers of limited staff time (struggling to 
incorporate screening into workloads) lack of qualified personnel to provide screening, 
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referrals or interventions still remain, but to a lesser extent.  It is also notable that in the pre-
guidelines survey more than 20% of respondents reported that ‘no one on their team had 
responsibility for MH’, this has decreased to 11%.  The demand for training remains high with 
training for the whole MDT a priority.  Requests for training in behavioural interventions and 
prescribing psychotropic medication have also increased post-guidelines.  
 
The ECFS Mental Health Working Group is engaged in facilitating MH screening to improve 
the health outcomes of patients and caregivers.21 The working group will build on the 
successes and attempt to address the difficulties raised by CF teams in implementing MH 
screening. The MHWG will continue to disseminate the guidelines by (a) translating the 
patient and clinician information into many more languages, (b) engage more ‘country 
captains’ who are able to network in their country and language, (c) deliver training courses 
to fulfil the requested training needs. There is much work to do but we have overcome the 
challenges of different healthcare systems and language barriers, so that two-years post-
publication of the guidelines, MH screening is both feasible, acceptable and gaining 
momentum across Europe. 
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Online supplement 1 
Mental Health Survey to CF Centres  
 
1. Please indicate your role on the CF team:  
Adult Physician  
Nurse  
Paediatrician  
Psychiatrist  
Psychologist  
Social Worker  
Other (please specify):  
Mental Health Screening and Intervention: Survey  
2. Are you the Centre Director?  
Yes  
No  
 
3. In which country do you live?  
Mental Health Screening and Intervention: Survey of  
4. Is your centre:  
Adults  
Paediatrics  
Both  
Mental Health Screening and Intervention: Survey of  
5. Approximately how many patients attend your Centre?  
Adults:  
Paediatrics:  
Mental Health Screening and Intervention: Survey of  
6. Do you currently have someone on your CF team whose 
primary role is to address mental health issues?  
Adult Physician  
Nurse  
Paediatrician  
Psychiatrist  
Psychologist  
Social Worker  
No one holds this role  
Other (please specify)  
 
7. Are you aware of the CF Mental Health Guidelines?  
Yes  
No  
Vaguely  
Mental Health Screening and Intervention: Survey  
8. If you are aware of the CF Mental Health Guidelines: Do 
you agree with the Guidelines?  
Yes  
Do not know  
Some recommendations  
No Con 
I 
9. Which professional/s do you think should be responsible 
for mental health screening? (Tick all that apply)  
Adult Physician  
Centre Director  
Nurse  
Paediatrician  
Psychiatrist  
Psychologist  
Social Worker  
No one  
Other (please specify)  
 
 
10. Is your clinic screening for mental health issues?  
Yes  
No (if no, please go to question 26)  
Health Screening and Intervention: Survey of  
11. Were you able to implement screening as part of your 
regular work schedule?  
Yes  
Yes, but not consistently  
No (specify additional resources/training required)  
 
12. Which screening tools for measuring anxiety and 
depression do you currently use? (Tick all that apply)  
Patient Health Questionnaire – 2 (PHQ2)  
Patient Health Questionnaire – 8 (PHQ8)  
Patient Health Questionnaire – 9 (PHQ9)  
Generalised Anxiety Disorder – 7 (GAD7)  
Other (please specify)  
 
13. What method do you use to screen patients? (Tick all 
that apply)  
Computer  
Paper  
Tablet  
Other (please specify)  
 
14. Approximately what percentage of adult patients have 
you been able to screen in the last year?  
<25%  
25% - 49%  
50% - 74%  
75% +  
Not Appropriate  
 
15. Approximately what percentage paediatric (age 12+ 
years) patients have you been able to screen in the last 
year?  
<25%  
25% - 49%  
50% - 74%  
75% +  
Not Appropriate  
 
16. Approximately what percentage of caregivers have you 
been able to screen in the last year?  
<25%  
25% - 49%  
50% - 74%  
75% +  
Not Appropriate  
 
17. If you are using the PHQ8/9 or GAD7: Approximately 
how many required intervention because of 
moderate/severe levels of symptoms (above 10 points)? If 
you are not using these recommended screening tools or do 
not have this information, please go to question 19  
Adults:  
Caregivers:  
Paediatrics (12+ years):  
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18. How many required immediate intervention because of 
indicated suicidality? If you are not using these 
recommended screening tools or do not have this 
information, please go to question 19. 
Adults:  
Caregivers:  
Paediatrics (12+ years):  
 
19. Have you been able to provide the recommended follow-
up (according to the guidelines) in your Centre?  
Yes  
Sometimes  
No  
Do not know  
 
20. Do you offer preventative strategies?  
Yes (please describe in the text box)  
No  
 
21. Do you have referral pathways for Mental Health issues 
available to you within your clinic?  
Yes  
No  
Do not know  
 
22. Have you developed a plan for patients or caregivers 
who screen positive for suicide risk?  
Yes  
No  
 
23. Have you referred outside your CF Centre? (But in your 
hospital)  
Yes  
Sometimes  
No  
Do not know  
 
24. Have you referred outside your hospital?  
Yes  
Sometimes  
No  
Do not know  
 
25. What benefits have you seen from implementing mental 
health screening at your CF Centre? (Tick all that apply)  
Easier to initiate conversations with patients and caregivers 
about Mental Health issues  
Greater awareness among caregivers of Mental Health 
issues  
Greater awareness among health professionals of Mental 
Health issues  
Mental Health being destigmatised  
Other (please specify)  
 
 
 
 
 
 
 
 
26. Have you experienced any barriers in implementing 
Mental Health screening at your CF Centre? (Tick all that 
apply)  
Difficult logistics (e.g. how/where to store data)  
Ethical dilemmas  
Lack of interest from CF team  
Lack of qualified personnel to provide screening  
Lack of qualified personnel to provide referrals or 
interventions  
Maintaining patient confidentiality/privacy  
Patient burden (e.g. concern about patients’ time)  
Patient unwillingness/refusal to complete questionnaires  
Space limitations  
Other (please specify)  
 
27. What type of assistance would be helpful in 
implementing an annual mental health screening program 
for all patients in your Centre? (tick all that apply)  
Access to a list of local mental health resources and referrals  
Access to electronic tools (e.g. tablets, computers) for 
administration and scoring  
Access to mental health hotline for guidance  
Additional funds to support a mental health professional  
Training  
Other comments:  
 
28. Would you be interested in training in any of the 
following at the European CF Society (ECFS) conference? 
(Tick all that apply)  
Behavioural interventions (e.g. Cognitive Behavioural 
Therapy)  
Counselling or supportive therapy  
Mental health screening  
Mental health training for the CF team  
Prescribing medications for depression or anxiety  
Preventative education  
Other comments: 
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Online Supplement 2. 
List of Countries and number of responding centres 
Austria (7) 
Belgium (7) 
Bulgaria (1) 
Croatia (2) 
Czech Republic (3)  
Denmark (3) 
France (21) 
Germany (21) 
Greece (3) 
Hungary (2) 
Ireland (3) 
Israel (5) 
Italy (8) 
Macedonia (4) 
Netherlands (14) 
Norway (2) 
Poland (5) 
Portugal (4) 
Russia (2) 
Serbia (2) 
Slovakia (2) 
Slovenia (2) 
Spain (12) 
Sweden (4) 
Switzerland (8) 
Turkey (1) 
United Kingdom (36) 
Ukraine (1) 
No Country Given (2) 
187 responses from 28 different countries 
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Online Supplement 3. 
Depression and Anxiety Scales employed other than those recommended (n) 
Hospital Anxiety and Depression Scale (HADS) 9 
Beck’s Youth/Depression Inventory (BDI, BYI-D, BYI-A, BYI-S) 3 
Hamilton Depression Scale (HAM-D) 1 
State-trait Anxiety Inventory (STAI) 1 
Centre for Epidemiologic Studies Depression Scale (CES-D) 1 
Depression Anxiety Stress Scale (DASS) 1 
Child Schedule for Affective Disorders and Schizophrenia (KiddieSads) 1 
Paediatric Index of Emotional Distress (PI-ED) 1 
Revised Children’s Anxiety and Depression Scale (RCADS) 1 
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Table 1. Characteristics of CF Centres and Respondents  
Type of Centre 
   Adult 
   Paediatric 
   Both 
   Not disclosed 
% (n) 
18.7 (35) 
26.2 (49) 
52.4 (98) 
2.7 (5) 
Profession of Respondent  
   Psychologist 
   Paediatrician 
   Adult Physician 
   Nurse 
   Social Worker 
   Psychiatrist 
   Other profession* 
 
% (n) 
33.7 (63) 
29.4 (55) 
11.2 (21) 
10.7 (20) 
3.7 (7) 
1.1 (2) 
10.2 (19) 
*Other profession e.g. Dietitian, Physiotherapist, Research Co-ordinator.  
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Table 2. Responsibility for Mental Health (multiple responses permitted) 
Currently responsible for Mental Health (n=170) 
 
Should be responsible for Mental Health (n=187) 
 
Psychologist 
Social Worker 
Adult Physician 
Paediatrician 
Psychiatrist 
Nurse 
Centre Director 
Don’t know 
No one holds this role 
Joint psychologist & Social Worker 
 
%(n) 
71.8 (122) 
5.3 (9) 
0.6 (1) 
4.1 (7) 
3.6 (6) 
0.0 (0) 
0.0 (0) 
0.6 (1) 
11.2 (19) 
2.9 (5) 
 
Psychologist 
Social Worker 
Adult Physician 
Paediatrician 
Psychiatrist 
Nurse 
Centre Director 
Don’t know 
No one  
%(n) 
89.6 (162) 
34.2 (64) 
29.4 (55) 
29.4 (55) 
27.3 (51) 
35.8 (67) 
7.5 (14) 
0.5 (1) 
0.5 (1) 
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Table 3. Benefits, barriers and further training needs (multiple responses permitted) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
 
Pre-guideline European survey data in parenthesis8   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Benefits of Screening  
      Easier to initiate conversations with patients/caregivers about MH 
      Greater awareness of MH issues among health professionals 
      Greater awareness of MH issues among patients 
      Greater awareness of MH issues among caregivers 
      Mental Health being destigmatised  
 
% of those screening (n=94) 
70.2 
63.8 
63.8 
48.9 
51.0 
Barriers to Screening 
      Limited staff time 
      Lack of qualified personnel to provide screening 
      Lack of qualified personnel to provide referrals or interventions 
      Patient unwillingness or refusal to complete questionnaires 
      Patient burden (e.g. concern about patient time and availability) 
      Difficult logistics (e.g. how and where to store data) 
 
% of all respondents (n=187) 
69.9 (75.8) 
34.6 (60.6) 
31.6 (56.0) 
22.6 (21.6) 
21.8 (29.5) 
19.6 (31.0) 
Further training needs 
      Mental Health training for CF team 
      Preventative education 
      Mental Health screening 
      Counselling or supportive therapy 
      Behavioural interventions (e.g. CBT) 
      Prescribing medications for anxiety or depression 
 
% of all respondents (n=187) 
68.0 
56.0  
55.2 (53.0) 
49.6 (52.5) 
40.0 (31.4) 
24.8 (17.6) 
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 Figure 1. Ability to provide recommended follow up. 
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Figure 2. Guideline awareness and implementation in CF Centres:  Eastern and Western Europe 
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